Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ensysce Biosciences Inc ENSC

Alternate Symbol(s):  ENSCW

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology... see more

Recent & Breaking News (NDAQ:ENSC)

Ensysce Biosciences Regains Compliance with Nasdaq

ACCESS Newswire May 28, 2024

Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform

ACCESS Newswire May 20, 2024

Ensysce Biosciences Reports First Quarter 2024 Financial Results

ACCESS Newswire May 13, 2024

Ensysce Biosciences' CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine

ACCESS Newswire April 25, 2024

Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published

ACCESS Newswire April 19, 2024

Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

ACCESS Newswire April 9, 2024

MRC Global Announces Agreement with Engine Capital and Appointment of Daniel Silvers to the Board of Directors

GlobeNewswire April 2, 2024

Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results

ACCESS Newswire March 15, 2024

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

ACCESS Newswire February 27, 2024

Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection

ACCESS Newswire February 21, 2024

Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript

ACCESS Newswire February 15, 2024

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds

ACCESS Newswire February 13, 2024

Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference

ACCESS Newswire February 6, 2024

Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain

ACCESS Newswire January 31, 2024

Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting

ACCESS Newswire January 25, 2024

Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR

ACCESS Newswire January 23, 2024

Ensysce Biosciences Issues 2024 Shareholder Letter

ACCESS Newswire January 8, 2024

Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023

ACCESS Newswire December 19, 2023

Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic

ACCESS Newswire December 14, 2023

Ensysce Biosciences Discusses TAAP and MPAR(R) Applications and OncoZenge Partnership with The Stock Day Podcast

ACCESS Newswire December 11, 2023